November 3, 2016
Horizon’s urea cycle disorder drug to sell in Canada
Horizon Pharma has announced that Ravicti (glycerol phenylbutyrate) Oral Liquid is now available in Canada through its affiliate….
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 3, 2016
Alkermes awards $1M to support people affected by mental health
Alkermes, a global biopharmaceutical company developing medicines for the treatment of central nervous system…
November 3, 2016
LeoPharma and Morphosys join forces to fight skin diseases
LEO Pharma and MorphoSys AG have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
November 3, 2016
ValiRx’s new cancer drug progresses into the clinic
ValiRx’s new cancer drug VAL401 progresses into the clinic
November 3, 2016
Positive outcome of Mereo’s phase 1 study of acute exacerbations of COPD drug
Mereo reports positive outcome of its phase 1 study of acute exacerbations of COPD drug
November 3, 2016
Strides, Mylan settle Regulatory and General Claims on Agila transaction, Strides gets $30M
Strides and Mylan have agree to settle Regulatory and General Claims on Agila transaction.
November 2, 2016
Eli Lilly, Incyte’s rheumatoid arthritis drug studies show positive effect
Eli Lilly and Company and Incyte Corporation have announced on Wednesday that new data from RA-BEACON – a pivotal phase 3 study…
November 2, 2016
Allergan announces $10 B accelerated share repurchase, initiation of cash dividend in 2017
Allergan has completed its initial $5 billion in share repurchases under its previously announced share repurchase program…
November 2, 2016
GE Healthcare, Valneva join forces to create cell culture medium for vaccine
GE Healthcare and Valneva have joined forces to create cell culture medium for vaccine
November 2, 2016
Abzena, Gilead drop Chron Disease drug after Phase II study
Abzena has issued a statement in which it notes that during the conference call to accompany Gilead Sciences Inc.’s (‘Gilead’) announcement of third quarter